Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
about
Work-related barriers and facilitators to antiretroviral therapy adherence in persons living with HIV infectionLong-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort studyDeveloping useful highly active antiretroviral therapy adherence measures for India: the Prerana study.Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysisSuboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells.Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon.Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks.'Simply forgot' is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence.Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression.Comparing adherence to two different HIV antiretroviral regimens: an instrumental variable analysis.
P2860
Q28389395-CC7EBF05-1407-42CA-AB74-23370DF65045Q28485373-323623D6-D7B4-4DE0-915C-39FE462800DCQ33699710-576EAA8C-DF1B-4B4F-81E3-6DD9F7DE91A4Q33988153-9270F7FB-6A43-4CC0-894F-ABACA8C25A9EQ34812918-88CB8DC2-BD4A-47EE-9636-8388FDF6DA6BQ35800805-389CE930-289A-478C-A60C-53B5FE2323E7Q37611687-677612A6-06FF-4942-A3F3-09B9DA42B527Q39007008-2E9EA654-AFFE-435A-93E2-EF76029187ABQ41951619-6836F737-EA44-4E39-80C8-CDBCA0980E89Q42620819-EEF8D80E-6E74-42DF-943B-05F29BCBDDDFQ43172781-A24F4EE0-6E00-4A43-A38D-FCDB0BDCA68CQ43970860-40EB22BB-9D43-4BBC-8C17-AC2750659DEBQ46544839-15B1D6B5-D2B7-4BCE-B622-F2177FFCB6F9Q48631709-7342C2E7-4A8A-4DCF-A25F-11DE36284072
P2860
Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Resistance profiles and adhere ...... e rates in a randomized study.
@en
Resistance profiles and adhere ...... e rates in a randomized study.
@nl
type
label
Resistance profiles and adhere ...... e rates in a randomized study.
@en
Resistance profiles and adhere ...... e rates in a randomized study.
@nl
prefLabel
Resistance profiles and adhere ...... e rates in a randomized study.
@en
Resistance profiles and adhere ...... e rates in a randomized study.
@nl
P2093
P2860
P1433
P1476
Resistance profiles and adhere ...... e rates in a randomized study.
@en
P2093
Gerstoft J
Lundgren JD
Mathiesen LR
Pedersen C
P2860
P304
P356
10.1111/J.1468-1293.2004.00233.X
P577
2004-09-01T00:00:00Z